Polytherapy and Targeted Cancer Drug Resistance

Nilanjana Chatterjee1, Trever G Bivona1

  • 1Department of Medicine, University of California, San Francisco, 600 16(th) Street, Box 2140, Genentech Hall, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, 600 16(th) Street, Box 2140, Genentech Hall, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 600 16(th) Street, Box 2140, Genentech Hall, San Francisco, CA 94158, USA.

Trends in Cancer
|March 23, 2019
PubMed

Insights

Cancer drug resistance is a major challenge, driven by genetic and reversible mechanisms. Understanding these diverse strategies is key to developing new therapies to overcome treatment failure and tumor relapse.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Cancer treatment often faces challenges with drug resistance, leading to incomplete responses and tumor relapse.
  • While genetic mutations are known drivers, reversible proteomic and epigenetic factors also contribute to resistance.
  • Tumor microenvironment and heterogeneity significantly impact treatment efficacy and resistance development.

Purpose of the Study:

  • To discuss the diverse strategies cancers employ to evade drug response.
  • To explore the potential of combination, intermittent, and switching therapies in preventing resistance.
  • To highlight the role of epigenetic reprogramming in combating cancer drug resistance.

Main Methods:

  • Literature review and synthesis of current research on cancer drug resistance mechanisms.
  • Discussion of therapeutic strategies aimed at overcoming or preventing drug resistance.
  • Analysis of the interplay between tumor biology, microenvironment, and treatment response.

Main Results:

  • Cancer employs multifaceted strategies, including genetic and reversible mechanisms, to resist therapy.
  • Combination, intermittent, and switching therapies show promise in delaying or overcoming resistance.
  • Epigenetic reprogramming offers a potential avenue for combating established drug resistance.

Conclusions:

  • Addressing cancer drug resistance requires a comprehensive understanding of its diverse underlying mechanisms.
  • Innovative therapeutic approaches, including combination strategies and epigenetic modulation, are crucial for improving patient outcomes.
  • Further research into tumor heterogeneity and microenvironment interactions is essential for developing effective, durable cancer treatments.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.2K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.5K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
5.9K
Resistance and Conductance01:25

Resistance and Conductance

A conductor's DC resistance at a given temperature is influenced by its resistivity, length, and cross-sectional area. Resistivity is an inherent property of the conductor material, with annealed copper serving as the international standard for measurement. For instance, the resistivity of hard-drawn aluminum at 20 degrees Celsius is 61% of the standard conductivity of annealed copper.
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
508